News Releases

Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 25, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will

Mirum Pharmaceuticals Presents Data Demonstrating Long-term Durability of Treatment Effect of Maralixibat in Children With Cholestatic Liver Diseases

Statistically and clinically significant effects on pruritus, xanthomas and growth maintained for up to four years of treatment in Alagille syndrome Durable multi-parameter treatment response and correlation of response with increased bile acid synthesis in progressive familial intrahepatic

Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome Granted Cash, Cash Equivalents and Investments Balance of $153.6 million FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Announces Appointment of Ed Tucker as Chief Medical Officer

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 28, 2019-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the appointment of Ed Tucker , M.D.

Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome

Durability of Treatment Effect of Mirum Pharmaceuticals’ Maralixibat for Children With Alagille Syndrome Featured in Late Breaking Session at the Liver Meeting 2019

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 21, 2019-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that data on its program for

Mirum Pharmaceuticals to Present New Data at The Liver Meeting 2019

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 1, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that multiple maralixibat

Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference

FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 26, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will

Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 28, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today reported financial results for the

Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

FOSTER CITY, Calif. , July 17, 2019 /PRNewswire/ -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price

News Releases

News Releases

Header Menu